HIGHLIGHTS
- who: Adenocarcinoma via Anti-Tim- and collaborators from the The Second Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China have published the article: Enhanced Inhibitory Effect of DC-CIK Cells on Lung Adenocarcinoma via Anti-Tim-3 Antibody and Antiprogrammed Cell Death-1 Antibody and Possible Mechanism, in the Journal: Evidence-Based Complementary and Alternative Medicine of 31/07/2022
- what: The study investigated whether anti-Tim-3 and anti-PD1 antibodies could enhance the tumor-specific immune_response of DC-CIK cells and produce a more substantial . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.